



Published papers for the Schizophrenia Trial

Updated March 26, 2007

- Stroup, TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano G, Rosenheck RA, Keefe RSE, Miller A, Belz I, Hsiao JK for the CATIE Investigators. (2007) Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients with Chronic Schizophrenia after Discontinuing Perphenazine: A CATIE Study. *American Journal of Psychiatry*, 164, 415-427.
- Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RSE, McEvoy JP, Hsiao JK, Lieberman JA for the CATIE Investigators. (2007) Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE Study. *American Journal of Psychiatry*, 164, 428-436.
- Sullivan PF, Keefe RS, Lange LA, Lange EM, Stroup TS, Lieberman J, Maness PF. (2007) NCAM1 and neurocognition in schizophrenia. *Biological Psychiatry*, 61(7), 902-10.
- Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RSE, Swartz M, Perkins DO, Hsiao JK, Lieberman J for the CATIE Study Investigators. (2006) Cost-Effectiveness of Second Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. *American Journal of Psychiatry*, 163, 2080-2089.
- Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. (2006) Effectiveness of Switching Antipsychotic Medications. *American Journal of Psychiatry*, 163, 2090-2095.
- Lieberman JA. (2006) Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). *Archives of General Psychiatry*, 63(10),1069-72.
- Citrome L, Stroup TS. (2006) Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? *International Journal of Clinical Practice*, 60(8), 933-40.
- Lieberman JA, Hsiao JK. (2006) Interpreting the Results of the CATIE Study. *Psychiatric Services*, 57(8), 139.
- Lieberman JA. (2006) What the CATIE Study Means for Clinical Practice. Commentary. *Psychiatric Services*, 57(8), 1075.
- Rosenheck RA, Swartz MS, Lieberman JA. (2006) Introduction to the Special Section on CATIE Baseline Data: Practical Clinical Trials in Psychiatry: Studies of Schizophrenia From the CATIE Network. *Psychiatric Services*, 57(8), 1093.

- Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RSE, Rosenheck RA. (2006) Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial. *Psychiatric Services*, 57(8), 1094-101.
- Chwastiak LA, Rosenheck RA, McEvoy JP, Keefe RS, Swartz MS, Lieberman JA. (2006) Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia. *Psychiatric Services*, 57(8), 1102-9.
- Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, McGee M, Miller DD, Reimherr F, Khan A, Canive JM, Lieberman JA. (2006) Substance Use and Psychosocial Functioning in Schizophrenia Among New Enrollees in the NIMH CATIE Study. *Psychiatric Services*, 57(8), 1110-6.
- Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA. (2006) Components and correlates of family burden in schizophrenia. *Psychiatric Services*, 57(8), 1117-25.
- McEvoy JP. (2006) Introduction: An Overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study. *CNS Spectrums*, 11(7 Suppl 7), 4-8.
- Perkins DO. (2006) Clinical trials in schizophrenia with results for the real world. *CNS Spectrums*, 11(7 Suppl 7), 9-13.
- Meltzer HY, Bobo WV. (2006) Interpreting the Efficacy Findings in the CATIE Study: What Clinicians Should Know. *CNS Spectrums*, 11 (7 Suppl 7), 14-24.
- Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS. (2006) Low Rates of Treatment for Hypertension, Dyslipidemia and Diabetes in Schizophrenia: Data from the CATIE Schizophrenia Trial Sample at Baseline. *Schizophrenia Research*, 86(1-3), 15-22.
- Swanson J, Swartz M, van Dorn Richard, Elbogen E, Wagner R, Rosenheck R, Stroup S, McEvoy K, Lieberman J. (2006) A National Study of Violent Behavior in Persons with Schizophrenia. *Archives of General Psychiatry*, 63, 490-499.
- Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, Walker TM, Stroup TS, McEvoy JP, Lieberman JA. (2006) Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial. *Neuropsychopharmacology*. 31(9), 2033-46.
- McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Rosenheck RA, Swartz MS, Perkins DO, Keefe RSE, Davis CE, Severe J, Hsiao JK for CATIE Investigators. (2006) Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. *American Journal of Psychiatry*, 163, 600-610.
- Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RSE, Davis CE, Severe J, Hsiao JK for the CATIE Investigators. (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia after discontinuing a previous atypical antipsychotic. *American Journal of Psychiatry*, 163, 611-622.
- Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao JK, Lieberman J. (2006) Barriers to employment for people with schizophrenia. *American Journal of Psychiatry*, 163(3), 411-7.

- Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, Miller DD, Reimherr F, McGee M, Kahn A, Van Dorn R, Rosenheck RA, Lieberman JA. (2006) Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. *The Journal of Nervous and Mental Disease*, 194(3), 164-72.
- Stroup TS, Appelbaum PS. (2006) Evaluation of "Subject Advocate" Procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study. *Schizophrenia Bulletin*, 32(1), 147-52.
- Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA. (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. *Schizophrenia Research*, 80, 45-53.
- Keefe R, Bilder RM, Harvey PD, Davis S, Palmer B, McEvoy JP, Goldberg TE, Gold JM, Green MF, Swartz M, Stroup S, Rosenheck R, Perkins DO, Meltzer HY, Miller D, Canive J, Walker TM, Lieberman JA. (2005) Baseline neurocognitive assessment of 1364 patients with schizophrenia in the clinical antipsychotic trials for intervention effectiveness (CATIE) project. *Schizophrenia Bulletin*, 31(2), 361-362.
- Keefe R, Bilder RM, Palmer B, Harvey PD, Davis S, McEvoy J, Goldberg TE, Gold J, Green MF, Swartz M, Stroup S, Rosenheck R, Perkins D, Meltzer H, Lieberman JA. (2005) Baseline neurocognitive assessment of 1364 patients with schizophrenia in the clinical antipsychotic trials for intervention effectiveness (CATIE) project. *Biological Psychiatry*, 57(8), 79S-79S.
- Lieberman J, Stroup TS, McEvoy J, Swartz M, Rosenheck R, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *New England Journal of Medicine*, 353(12), 1209-1223.
- McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott ST, Lieberman JA. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. *Schizophrenia Research*, 80, 19-32.
- Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe RS, Stroup TS, Lieberman JA. (2005) The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. *Schizophrenia Research*, 80, 9-18.
- Miller D, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS, Lieberman JA. (2005) Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. *Schizophrenia Research*, 80, 33-43.
- Rosenheck RA, Stroup S, Keefe R, McEvoy J, Swartz M, Perkins D, Hsiao J, Shumway M, Lieberman J. (2005) Measuring outcome priorities and incorporating preferences in mental health status assessment of people with schizophrenia. *British Journal of Psychiatry*, 187, 529-536.

- Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, Kim S, Keefe R, Manschreck T, McEvoy J, Lieberman J. (2005) Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. *Schizophrenia Research*, 80, 1-8.
- Sernyak MJ, Leslie D, Rosenheck, R. (2003). Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications. *American Journal of Psychiatry*, 160(2), 310-315.
- Lieberman JA, Stroup TS. (2003). Guest editors' introduction: what can large pragmatic clinical trials do for public mental health care? *Schizophrenia Bulletin*, 29(1), 1-6.
- Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA. (2003). The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. *Schizophrenia Bulletin*, 29(1),15-31.
- Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. (2003). Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. *Schizophrenia Bulletin*, 29(1), 33-43.
- Keefe RS, Mohs RC, Bilder RM, Harvey PD, Green MF, Meltzer HY., et al. (2003). Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. *Schizophrenia Bulletin*, 29(1), 45-55.
- Davis SM, Koch GG, Davis CE, LaVange LM. (2003) Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. *Schizophrenia Bulletin*, 29(1), 73-80.
- Rosenheck R, Doyle J, Leslie D, Fontana A. (2003). Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. *Schizophrenia Bulletin*, 29(1), 81-93.